Author | Michael J. Pishvaian, MD, PhD | OncLive

Author | Michael J. Pishvaian, MD, PhD

Articles

Dr. Pishvaian on FDA Approval of Atezolizumab Plus Bevacizumab in HCC

May 29, 2020

Video

Michael J. Pishvaian, MD, PhD, discusses the FDA approval of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of patients with hepatocellular carcinoma (HCC).

x